(Q45991052)

English

Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy.

scientific article published in June 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19479613

Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy. (English)

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19479613

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Hyun-Gyung Goh

1

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19479613

Yoo-Jin Kim

2

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19479613

Dong-Wook Kim

3

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19479613

Hyeoung-Joon Kim

4

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19479613

Soo-Hyun Kim

5

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19479613

Se-Eun Jang

6

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19479613

Jeong Lee

7

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19479613

Dongho Kim

8

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19479613

Wan-Seok Kim

9

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19479613

Sa-Hee Park

10

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19479613

Il-Young Kweon

11

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19479613

publication date

1 June 2009

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19479613

Leukemia & Lymphoma

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19479613

50

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19479613

6

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19479613

944-951

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19479613

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190902926973

21 January 2018

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1080%2F10428190902926973

21 January 2018

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1080%2F10428190902926973

21 January 2018

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190902926973

21 January 2018

Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha

1 reference

https://api.crossref.org/works/10.1080%2F10428190902926973

21 January 2018

Discontinuation of imatinib therapy after achieving a molecular response

1 reference

https://api.crossref.org/works/10.1080%2F10428190902926973

21 January 2018

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

1 reference

https://api.crossref.org/works/10.1080%2F10428190902926973

21 January 2018

Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha

1 reference

https://api.crossref.org/works/10.1080%2F10428190902926973

21 January 2018

How I treat chronic myeloid leukemia in the imatinib era.

1 reference

https://api.crossref.org/works/10.1080%2F10428190902926973

21 January 2018

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

1 reference

https://api.crossref.org/works/10.1080%2F10428190902926973

21 January 2018

Identifiers

10.1080/10428190902926973

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19479613

1 reference

Europe PubMed Central

18 December 2017

http://europepmc.org/abstract/MED/19479613

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45991052&oldid=2104622488"